DBV Technologies | Betriebsaufwand



Operating Expenses Veränderung Datum
Acadia Pharmaceuticals USD 106.1M 112.66M 2024-12
Alnylam Pharmaceuticals USD 698.32M 120.5M 2024-12
Amarin USD 67.47M 549K 2024-09
BioMarin Pharmaceutical USD 585.91M 45.94M 2024-12
DBV Technologies USD 31.4M 3.6M 2024-09
Halozyme Therapeutics USD 122.51M 4.38M 2024-12
Incyte USD 877.18M 114.6M 2024-12
Insmed USD 334.86M 28M 2024-12
Ionis Pharmaceuticals USD 337.4M 54.93M 2024-12
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
PTC Therapeutics USD 275.66M 24.36M 2024-12
Sarepta Therapeutics USD 496.73M 51.76M 2024-12
Ultragenyx Pharmaceutical USD 287.15M 15.67M 2024-12
United Therapeutics USD 378.2M 27.6M 2024-12



DBV Technologies Betriebsaufwand - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Apr 2025.